The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
Rhea-AI Summary
The Oncology Institute (NASDAQ: TOI) completed a strategic refinancing, repaying its $86 million senior secured convertible note with Deerfield Partners. The repayment used a new $75 million OrbiMed term loan maturing in 2031 plus about $11 million of cash, aiming to boost liquidity, flexibility, and extend debt maturities without raising equity.
Positive
- Repaid entire $86 million senior secured convertible note with Deerfield Partners
- Secured new $75 million term loan from OrbiMed maturing in 2031
- Transaction is intended to increase liquidity and improve operating flexibility
- Refinancing significantly extends debt maturities, according to the company
- Completed without raising equity, avoiding immediate shareholder dilution
- Establishes committed funding from two leading healthcare financing institutions
Negative
- None.
Market reaction after debt refinancing agreement with OrbiMed: TOI +6.62% in the Jul 7 session
In the Jul 7 session, TOI gained 6.62%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -2.1% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Conference speaking engagement | Neutral | +0.0% | CMO scheduled to speak on value-based specialty care at APG conference. |
| May 13 | Investor conference participation | Neutral | +1.5% | CEO and CFO participation in B. Riley institutional investor conference. |
| May 07 | 1Q26 earnings report | Positive | -1.7% | Strong revenue growth and narrowed net loss with updated 2026 guidance. |
| Apr 27 | Earnings call scheduling | Neutral | +2.5% | Announcement of Q1 2026 earnings release date and conference call details. |
| Apr 13 | Medicare savings results | Positive | +7.1% | Reported $1.8M Medicare savings and improved per-episode performance metrics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent TOI news has generally seen price moves that align with the tone of the announcements, with the main divergence occurring around an earnings release.
Key Terms
senior secured convertible note financial
term loan financial
liquidity financial
debt maturities financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its
This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its
"We are pleased to support TOI in its next phase of growth," said Matthew Rizzo of OrbiMed. " We are excited to play a role in TOI’s expansion and development as it continues to scale and drive long term value for its patients and contracted payors."
About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 2.0 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Forward Looking Statement
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or TOI’s future financial or operating performance and are often identified by words such as “believe,” “expect,” “anticipate,” “plan,” “intend,” “may,” “will,” “estimate,” “continue,” “project,” “target,” or similar expressions.
These forward-looking statements include, without limitation, statements regarding TOI’s growth strategy, liquidity, working capital needs, access to financing (including any asset-based credit facilities), expected operational and financial performance, and market opportunities. These statements are based on current expectations, assumptions, and information available to management and are not guarantees of future performance.
Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of risks and uncertainties, including, among others: changes in the healthcare regulatory environment; reimbursement and payor dynamics; competitive pressures; TOI’s ability to execute on its growth and value-based care strategy; access to capital and liquidity; and the impact of litigation, government investigations, or other proceedings.
Additional factors that could cause actual results to differ materially are described in TOI’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of TOI’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date made, and TOI undertakes no obligation to update or revise these statements to reflect events or circumstances occurring after the date of this communication, except as required by law.
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
ICR Healthcare
TOI@icrhealthcare.com
